Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KD304
- Development stage
- Preclinical
- Lead developer
- Kwang Dong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KD304 is an investigational drug candidate being developed by Kwang Dong Pharmaceutical for the treatment of benign prostatic hyperplasia (BPH). Currently in the formulation research stage, KD304 is likely an incrementally modified drug (IMD) designed to improve upon existing BPH therapies, such as alpha-1 adrenergic receptor antagonists or 5-alpha reductase inhibitors. The project aims to optimize the delivery or efficacy of treatment for patients suffering from lower urinary tract symptoms associated with an enlarged prostate. As of early 2024, specific active ingredients and molecular targets for KD304 have not been publicly disclosed in the company's official pipeline documentation.
Beyond the preview
Go deeper on KD304.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KD304.